These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32009513)

  • 1. The direct-to-consumer market for stem cell-based interventions in Australia: exploring the experiences of patients.
    Waldby C; Hendl T; Kerridge I; Lipworth W; Lysaght T; Munsie M; Stewart C
    Regen Med; 2020 Jan; 15(1):1238-1249. PubMed ID: 32009513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rogue stem cell clinics.
    Murray IR; Chahla J; Frank RM; Piuzzi NS; Mandelbaum BR; Dragoo JL;
    Bone Joint J; 2020 Feb; 102-B(2):148-154. PubMed ID: 32009438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Industry Responsibilities in Tackling Direct-to-Consumer Marketing of Unproven Stem Cell Treatments.
    Master Z; Fu W; Paciulli D; Sipp D
    Clin Pharmacol Ther; 2017 Aug; 102(2):177-179. PubMed ID: 28695633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions.
    Turner L
    Perspect Biol Med; 2018; 61(1):7-24. PubMed ID: 29805145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Australian regulation of autologous human cell and tissue products: implications for commercial stem cell clinics.
    Ghinea N; Munsie M; Rudge C; Stewart C
    Regen Med; 2020 Feb; 15(2):1361-1369. PubMed ID: 32228372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulating the advertising and promotion of stem cell therapies.
    von Tigerstrom B
    Regen Med; 2017 Oct; 12(7):815-826. PubMed ID: 29112482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct-to-consumer marketing of stem cell interventions by Canadian businesses.
    Turner L
    Regen Med; 2018 Sep; 13(6):643-658. PubMed ID: 30255734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From the margins to mainstream: How providers of autologous 'stem cell treatments' legitimise their practice in Australia.
    MacGregor C; Petersen A; Munsie M
    Health (London); 2021 Jan; 25(1):51-68. PubMed ID: 31081381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The involvement of Canadian physicians in promoting and providing unproven and unapproved stem cell interventions.
    Ogbogu U; Du J; Koukio Y
    BMC Med Ethics; 2018 May; 19(1):32. PubMed ID: 29716594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stem cell clinics: risk of proliferation.
    Sissung TM; Figg WD
    Lancet Oncol; 2020 Feb; 21(2):205-206. PubMed ID: 32007195
    [No Abstract]   [Full Text] [Related]  

  • 11. Turning the Tide on Unproven Cell-Based Interventions.
    Ikonomou L; Weiss DJ
    Chest; 2020 Apr; 157(4):774-775. PubMed ID: 32252930
    [No Abstract]   [Full Text] [Related]  

  • 12. Marketing of healthcare services in Denmark: the concept of misleading advertising.
    Aagaard L
    Int J Clin Pharm; 2020 Dec; 42(6):1524-1527. PubMed ID: 32789762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emergence and popularisation of autologous somatic cellular therapies in Australia: therapeutic innovation or regulatory failure?
    McLean AK; Stewart C; Kerridge I
    J Law Med; 2014 Sep; 22(1):65-89. PubMed ID: 25341320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is multi-level marketing of nutrition supplements a legal and an ethical practice?
    Cardenas D; Fuchs-Tarlovsky V
    Clin Nutr ESPEN; 2018 Jun; 25():133-138. PubMed ID: 29779808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory claims made by US businesses engaged in direct-to-consumer marketing of purported stem cell treatments and exosome therapies.
    Turner L; Martinez JR; Najjar S; Arachchilage TR; Sahrai V; Wang JC
    Regen Med; 2023 Nov; 18(11):857-868. PubMed ID: 37867326
    [No Abstract]   [Full Text] [Related]  

  • 16. Marketing of unproven stem cell-based interventions: A call to action.
    Sipp D; Caulfield T; Kaye J; Barfoot J; Blackburn C; Chan S; De Luca M; Kent A; McCabe C; Munsie M; Sleeboom-Faulkner M; Sugarman J; van Zimmeren E; Zarzeczny A; Rasko JEJ
    Sci Transl Med; 2017 Jul; 9(397):. PubMed ID: 28679655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. US businesses engaged in direct-to-consumer marketing of perinatal stem cell interventions following the Food and Drug Administration's enforcement discretion era.
    Turner L; Wang JC; Martinez JR; Najjar S; Rajapaksha Arachchilage T; Sahrai V
    Cytotherapy; 2024 Apr; 26(4):393-403. PubMed ID: 38340106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory loophole enables unproven autologous cell therapies to thrive in Australia.
    Munsie M; Pera M
    Stem Cells Dev; 2014 Dec; 23 Suppl 1():34-8. PubMed ID: 25457959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in the Regulation of Autologous Stem Cell Interventions in the United States.
    Sipp D
    Perspect Biol Med; 2018; 61(1):25-41. PubMed ID: 29805146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct-to-consumer stem cell marketing and regulatory responses.
    Sipp D
    Stem Cells Transl Med; 2013 Sep; 2(9):638-40. PubMed ID: 23934911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.